Proto-Oncogene Proteins c-abl
"Proto-Oncogene Proteins c-abl" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Non-receptor tyrosine kinases encoded by the C-ABL GENES. They are distributed in both the cytoplasm and the nucleus. c-Abl plays a role in normal HEMATOPOIESIS especially of the myeloid lineage. Oncogenic transformation of c-abl arises when specific N-terminal amino acids are deleted, releasing the kinase from negative regulation.
| Descriptor ID |
D016315
|
| MeSH Number(s) |
D08.811.913.696.620.682.725.500 D12.776.624.664.700.167
|
| Concept/Terms |
Proto-Oncogene Proteins c-abl- Proto-Oncogene Proteins c-abl
- Proto Oncogene Proteins c abl
- c-abl, Proto-Oncogene Proteins
- Proto-Oncogene Proteins abl
- Proteins abl, Proto-Oncogene
- Proto Oncogene Proteins abl
- abl, Proto-Oncogene Proteins
- c-abl Proteins
- c abl Proteins
- abl Proto-Oncogene Products
- Products, abl Proto-Oncogene
- Proto-Oncogene Products, abl
- abl Proto Oncogene Products
- abl Proto-Oncogene Proteins
- Proto-Oncogene Proteins, abl
- abl Proto Oncogene Proteins
|
Below are MeSH descriptors whose meaning is more general than "Proto-Oncogene Proteins c-abl".
Below are MeSH descriptors whose meaning is more specific than "Proto-Oncogene Proteins c-abl".
This graph shows the total number of publications written about "Proto-Oncogene Proteins c-abl" by people in this website by year, and whether "Proto-Oncogene Proteins c-abl" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1998 | 0 | 1 | 1 |
| 2002 | 1 | 1 | 2 |
| 2004 | 0 | 1 | 1 |
| 2009 | 0 | 1 | 1 |
| 2011 | 0 | 1 | 1 |
| 2014 | 0 | 1 | 1 |
| 2023 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Proto-Oncogene Proteins c-abl" by people in Profiles.
-
Golovine K, Abalakov G, Lian Z, Chatla S, Karami A, Chitrala KN, Madzo J, Nieborowska-Skorska M, Huang J, Skorski T. ABL1 kinase as a tumor suppressor in AML1-ETO and NUP98-PMX1 leukemias. Blood Cancer J. 2023 03 23; 13(1):42.
-
Blanchard Z, Mullins N, Ellipeddi P, Lage JM, McKinney S, El-Etriby R, Zhang X, Isokpehi R, Hernandez B, Elshamy WM. Geminin overexpression promotes imatinib sensitive breast cancer: a novel treatment approach for aggressive breast cancers, including a subset of triple negative. PLoS One. 2014; 9(4):e95663.
-
Tiwary R, Yu W, Sanders BG, Kline K. a-TEA cooperates with chemotherapeutic agents to induce apoptosis of p53 mutant, triple-negative human breast cancer cells via activating p73. Breast Cancer Res. 2011 Jan 07; 13(1):R1.
-
Kim KI, Park J, Ahn KS, Won NH, Kim BK, Shin WG, Yoon SS, Oh JM. Molecular characterization and prognostic significance of FLT3 in CML progression. Leuk Res. 2010 Aug; 34(8):995-1001.
-
Rawe VY, Payne C, Navara C, Schatten G. WAVE1 intranuclear trafficking is essential for genomic and cytoskeletal dynamics during fertilization: cell-cycle-dependent shuttling between M-phase and interphase nuclei. Dev Biol. 2004 Dec 15; 276(2):253-67.
-
Emerson MM, Van Vactor D. Robo is Abl to block N-Cadherin function. Nat Cell Biol. 2002 Oct; 4(10):E227-30.
-
Cong F, Tang J, Hwang BJ, Vuong BQ, Chu G, Goff SP. Interaction between UV-damaged DNA binding activity proteins and the c-Abl tyrosine kinase. J Biol Chem. 2002 Sep 20; 277(38):34870-8.
-
Kyono WT, de Jong R, Park RK, Liu Y, Heisterkamp N, Groffen J, Durden DL. Differential interaction of Crkl with Cbl or C3G, Hef-1, and gamma subunit immunoreceptor tyrosine-based activation motif in signaling of myeloid high affinity Fc receptor for IgG (Fc gamma RI). J Immunol. 1998 Nov 15; 161(10):5555-63.